Floatz logo

Gefitinib

Lung Large Cell Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Lung Large Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 4A
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Vinorelbine
AIO-Studien-gGmbH
Phase 3BB
Docetaxel
Korean South West Oncology Group
Phase 3BB

View all 31 →

Same molecule, other indications

Gefitinib is also rated in:

central nervous system neoplasmDormant
BBB
Indicative · Phase 2
73 / 100
View asset →
gliosarcomaDormant
BB
Indicative · Phase 2
71 / 100
View asset →
lung adenocarcinoma in situDormant
BB
Indicative · Phase 3
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →